Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

by Zhang, Joshua , Ejzykowicz, Flavia , Oyervides Juárez, Victor M , Barrios, Carlos , Porta, Camillo , Maurer, Matthew A , Choueiri, Toni K , Bedke, Jens , Apolo, Andrea B , Burotto, Mauricio , Zurawski, Bogdan , Schwab, Gisela M , Tomita, Yoshihiko , Powles, Thomas , Kowalyszyn, Rubén , Żołnierek, Jakub , Goh, Jeffrey C , Mizuno, Ryuichi , Richardet, Martin , Simsek, Burcin , Basso, Umberto , Hsieh, James J , Shah, Amishi Y , Hamzaj, Alketa , Kessler, Elizabeth R , Bourlon, Maria T , Escudier, Bernard , Pook, David , Motzer, Robert J , Feregrino, Juan P , Suárez, Cristina

in Adult / Adverse events / Aged / Aged, 80 and over / Anilides - administration & dosage / Anilides - adverse effects / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / B7-H1 Antigen - antagonists & inhibitors / Cancer therapies / Carcinoma, Renal Cell - drug therapy / Carcinoma, Renal Cell - mortality / Committees / Drug dosages / Female / Humans / Immunotherapy / Inhibitor drugs / Intention to Treat Analysis / Kidney cancer / Kidney Neoplasms - drug therapy / Kidney Neoplasms - mortality / Kinases / Male / Metastasis / Middle Aged / Monoclonal antibodies / Nivolumab - administration & dosage / Nivolumab - adverse effects / Progression-Free Survival / Proportional Hazards Models / Pyridines - administration & dosage / Pyridines - adverse effects / Quality of Life / Receptor Protein-Tyrosine Kinases - antagonists & inhibitors / Renal cell carcinoma / Signal transduction / Statistical analysis / Sunitinib - adverse effects / Sunitinib - therapeutic use / Survival Analysis / Targeted cancer therapy / Vascular endothelial growth factor

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2021

Confirm

Do you wish to request the book?

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Zhang, Joshua,

Ejzykowicz, Flavia,

Oyervides Juárez, Victor M,

Barrios, Carlos,

Porta, Camillo,

Maurer, Matthew A,

Choueiri, Toni K,

Bedke, Jens,

Apolo, Andrea B,

Burotto, Mauricio,

Zurawski, Bogdan,

Schwab, Gisela M,

Tomita, Yoshihiko,

Powles, Thomas,

Kowalyszyn, Rubén,

Żołnierek, Jakub,

Goh, Jeffrey C,

Mizuno, Ryuichi,

Richardet, Martin,

Simsek, Burcin,

Basso, Umberto,

Hsieh, James J,

Shah, Amishi Y,

Hamzaj, Alketa,

Kessler, Elizabeth R,

Bourlon, Maria T,

Escudier, Bernard,

Pook, David,

Motzer, Robert J,

Feregrino, Juan P,

Suárez, Cristina

2021

Overview

In a randomized trial involving patients with previously untreated advanced renal-cell carcinoma, nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free and overall survival and the likelihood of response. A total of 19.7% of the patients in the combination group discontinued one or both of the trial drugs prematurely.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Anilides - administration & dosage

/ Anilides - adverse effects

/ Antineoplastic Agents - adverse effects